Prevalence and Clinical Significance of Antiphospholipid Antibodies in Hospitalized Patients With COVID-19 Infection

Navkirat Kahlon 1, Pejma Shazadeh Safavi 2, Ziad Abuhelwa 2, Taha Sheikh 1, Cameron Burmeister 2, Sishir Doddi 3, Ragheb Assaly 4, William Barnett 5

1. Hematology and Medical Oncology, The University of Toledo Medical Center, Toledo, USA 2. Internal Medicine, The University of Toledo Medical Center, Toledo, USA 3. Medicine, The University of Toledo College of Medicine and Life Sciences, Toledo, USA 4. Pulmonary/Critical Care Medicine, The University of Toledo Medical Center, Toledo, USA 5. Biostatistics and Epidemiology, The University of Toledo Medical Center, Toledo, USA

Corresponding author: Navkirat Kahlon, navkiratkaurpannu@gmail.com

Abstract

Background: Coronavirus disease 2019 (COVID-19) infection is associated with an increased risk of arterial thromboembolic events (ATE) and venous thromboembolic events (VTE). Hypercoagulability associated with COVID-19 infection is multifactorial, and underlying pathogenic mechanisms potentially responsible for thrombosis include inflammation resulting in endothelial damage, platelet activation and the presence of antiphospholipid antibodies (APAs). Antiphospholipid antibody syndrome is one of the very few causes which is associated with venous and arterial thromboembolic events. COVID-19 patients have a high prevalence of APAs as well as both ATE and VTE, but their clinical significance in COVID-19 patients is not fully understood yet.

Objectives: In this study, we intend to find the prevalence of APAs in hospitalized COVID-19 patients at the time of diagnosis and determine whether their presence has any clinical significance.

Methods: This is a retrospective single-institution study involving patients hospitalized for the management of COVID-19 infection at The University of Toledo Medical Center. After obtaining approval from the biomedical institutional review board at The University of Toledo, antiphospholipid antibody (APA) testing was done on pre-stored blood samples of these patients and hospital charts were reviewed till six months from the positive COVID-19 test result. Two groups were created based on the patients’ APA testing results (APA positive and APA negative) and used for statistical comparison. Any patients with positive lupus anticoagulant (LA) or abnormal titers APA antibodies were labeled as positive. Demographic data, prognostic outcomes and laboratory values were compared either using Mann-Whitney U-test for continuous variables or Fisher’s exact test for categorical variables.

Results: The prevalence of APAs in hospitalized COVID-19 patients at the time of diagnosis was 39.3% in this study. There was no difference in demographic variables between the APA-positive and APA-negative groups. The prevalence of APAs was higher in smokers, where 91% of the APA-positive patients were smokers. There was no statistically significant difference in prognostic outcomes including six-month mortality between APA-positive and APA-negative patients. The comorbidity profile was the same in the two groups. APA-positive patients were found to have lower nadir of absolute lymphocyte count and higher nadir levels of C-reactive protein during hospitalization.

Conclusions: The prevalence of APA positivity in hospitalized COVID-19 patients is higher in our study than in historical studies involving non-COVID-19 hospitalized patients, particularly in smokers. However, there is no correlation between APA positivity and prognostic outcomes including six-month mortality. At this point, it is unclear whether APAs are just bystanders or have a pathogenic role. Routine testing of APA in COVID-19 patients is not indicated. Further prospective studies to elucidate the persistence and clinical implications of APAs are needed.

Keywords: c-reactive protein (crp), covid-related hypercoagulability, lymphocyte count, hospitalized, prognosis, mortality, clinical implications, prevalence, antiphospholipid antibodies, covid-19

Introduction

Coronavirus disease 2019 (COVID-19) infection is associated with arterial thromboembolic events (ATE) and venous thromboembolic events (VTE); however, there is substantial variance in the incidence of such events in the literature secondary to variability in patient characteristics and study protocols. Increased prothrombin time (PT), activated partial thromboplastin time (APTT), D-dimer and fibrinogen have been used as serologic markers with sensitivity and specificity noted to be above 80th percentile and negative
predictive values above 90th percentile in the detection of acute VTE [1].

Current literature supports that the hypercoagulability in COVID-19 infection is multifactorial. The proposed main factors predisposing COVID-19 patients to thrombosis include inflammation resulting in endothelial damage, platelet activation, hyperviscosity and the presence of antiphospholipid antibodies (APAs) [2]. Various underlying pathogenic mechanisms contributing to hypercoagulability have been investigated. Systemic cytokines responsible for atherosclerotic plaque rupture have been implicated in the inflammation and endovascular damage in COVID-19, which promotes a prothrombotic milieu locally [3-5]. It is also thought that angiotensin-converting enzyme 2 (expressed on myocytes and vascular endothelial cells) which acts as a receptor for COVID-19 contributes to endovascular injury [5-7]. APAs are thought to play a role in endothelial activation in COVID-19 [8].

APAs can be present in 1%-5% of the healthy population and are known to cause an autoimmune disorder called antiphospholipid syndrome (APS). APS is the most common form of acquired thrombophilia. The diagnostic criterion for APS includes the presence of both clinical criteria (recurrent venous or arterial thrombosis and/or fetal loss) and laboratory criteria (presence and persistence of APAs). Numerous APAs have been identified, but only a few are part of the diagnostic criteria for APS. The antibodies which are part of the clinical criteria for APS include lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-beta 2-glycoprotein I antibodies (aβ2GPI). Specifically, the immunoglobulin G (IgG) and immunoglobulin M (IgM) subclasses are included in the APS laboratory criteria [9,10]. COVID-19 patients have a high prevalence of APAs as well as both ATE and VTE, but their clinical significance in COVID-19 patients is not fully understood yet.

The presence of APAs in COVID-19 patients was brought to light in some case reports initially. In 2020, a case series of three critically ill COVID-19 patients who tested positive for APAs was reported with one patient suffering multiple bilateral cerebral infarcts and limb ischemia [11]. These cases triggered some further research regarding APAs in the context of COVID-19. APAs are known to be associated with elevated APTT. In a study involving COVID-19 patients, a subset of patients with elevated APTT was tested for the presence of APA utilizing dilute Russell’s viper venom time and lupus anticoagulant-sensitive APTT. Of those patients with elevated APTT, 91% were APA positive [10]. The clinical and laboratory data from the abovementioned studies involving COVID-19 patients seemed to suggest that APAs could be one of the contributing factors to thrombosis. As of note, antiphospholipid syndrome (primary or secondary) is one of the few causes associated with both arterial and venous thromboembolic events as seen in COVID-19 infection. All these initial findings further strengthened the interest of researchers in studying the role of APAs in COVID-19 patients. In this retrospective single-institution study, we intend to find the prevalence of APAs in hospitalized COVID-19 patients at the time of their initial presentation. Secondary objectives include determining whether the presence of APAs at initial diagnosis has any clinical significance, specifically looking at prognostic outcomes, i.e., six-month mortality, renal failure requiring dialysis, thrombotic events, need for mechanical ventilation, rehospitalizations, discharge disposition and the highest level of hospital care. Another secondary objective is to determine correlation of APAs at presentation with the known prognostic laboratory parameters for COVID-19 infection severity or laboratory parameters determining organ function.

Materials And Methods

The approval for this retrospective study conducted at the University of Toledo Medical Center was obtained from the biomedical institutional review board (IRB), IRB number: 300722-UT. Patients ≥18 years old who were hospitalized for COVID-19 infection from March 20, 2020 to June 30, 2021 and had adequate and viable samples to run LA testing. The cut-off level used to define positive antibody testing was >10.9 IgG phospholipid units (GPL) for aCL immunoglobulin G (IgG) and immunoglobulin M (IgM), >19.9 GPL for ACL immunoglobulin G (IgG), >19.9 GPL for aβ2GPI IgM and >19.9 GPL aβ2GPI IgG per institutional laboratory cut-off levels. LA testing was reported as positive or negative per institutional laboratory protocol. The laboratory personnel who tested the samples were blinded to clinical data. The charts were reviewed six months after the date of the positive COVID-19 test. Once the APA panel had been run and charts were reviewed, data were coded and securely stored so that only the investigator and authorized staff could access it to ensure confidentiality. Only de-identified data were analyzed and have been reported. Two groups were created based on the patients’ APA testing results, i.e., APA positive (+) and APA negative (-) and used for statistical comparison. Any patients with positive LA or abnormal titers APA antibodies were labeled as positive.
The primary objective of this study was to determine the prevalence of APAs in plasma of hospitalized COVID-19 patients. The secondary objective was to determine whether there is any correlation between the presence of APAs with adverse outcomes, i.e., six-month mortality, renal failure requiring dialysis, thrombotic events, need for mechanical ventilation, rehospitalizations, discharge disposition and the highest level of hospital care. Other secondary objectives were to determine demographic trends for APA-positive patients and the correlation between laboratory values known to be associated with poor prognosis or organ dysfunction and the presence of APAs in COVID-19 patients. Unfortunately, being a retrospective study, imaging studies such as computed tomography angiogram (CTA) or venous Doppler ultrasound were not available for most of these patients. As a result, we were unable to detect and report the presence or absence of asymptomatic thrombosis which would have been an important adverse effect of interest.

Outcomes and laboratory values were compared using non-parametric methods due to the small sample size and non-normality of the data. The Mann-Whitney U-test was used for continuous variables and Fisher’s exact test for categorical variables. All analyses were performed using R 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria), and an alpha level of 0.05 was considered statistically significant.

Results

A total of 28 patients were included in the final analysis. Seventeen of 28 patients (60.7%) were negative for APA, and 11 of 28 patients (39.3%) were positive for APA. Seven of 28 patients (25%) had positive aCL IgM with titers ranging from 11.4 to 28.1 GPL for aCL IgM-positive patients. Three of 28 patients (10.71%) had positive aCL IgG with titers ranging from 21.8 to 25.4 GPL for aCL IgG-positive patients. aβ2GPI IgM was present in two of 28 patients (7.14%) with titers ranging from 21.1 to 43.8 GPL for aβ2GPI IgM-positive patients. aβ2GPI IgG was not seen in any patients. LA testing could be done only in eight patients, and four of eight patients (50% of patients tested for LA, 14.2% of total number of patients) tested positive. Four of 28 patients (14.2%) had more than one positive APA test. No patient had a triple positive profile, i.e., positive testing for all three APAs (LA, aCL and aβ2GPI).

There was no difference in the selected demographic characteristics of APA-positive and APA-negative patients. The median age, gender distribution and racial/ethnic distribution were statistically similar between the two groups. The median age was 66 years (interquartile range (IQR): 53.00-68.00 years) for APA-negative patients and 60 years (IQR: 59.00-65.50 years) for APA-positive patients ($p = 0.925$). There was no statistically significant difference in the racial or ethnic distribution in APA-negative and APA-positive groups. Among APA-negative patients, 35.3% were White, 52.9% were Black, and 5.9% were Hispanic; among APA-positive patients, 54.5% were White, 36.4% were Black, and 0% were Hispanic ($p = 0.765$). The selected comorbidity profile which is commonly associated with vascular events was also similar between the two groups. In APA-negative and APA-positive groups, the past medical history of coronary artery disease was 29.4% and 18.2% ($p = 0.668$), atrial fibrillation was 29.4% and 18.2% ($p = 0.668$), stroke was 17.6% and 45.4% ($p = 0.120$), peripheral artery disease was 25.5% and 27.3% ($p = 1.000$) and cancer was 23.5% and 18.2% ($p = 1.000$), respectively. A statistically significant association between smoking history and APA positivity status was noted in our study. Ninety-one percent of patients who tested positive for APAs were smokers as compared to only 30% in APA-negative group. These results are summarized in Table 1.
| Patient Demographics and Comorbidities | APA- | APA+ | p-Value |
|----------------------------------------|------|------|---------|
| No. of patients                        | 17   | 11   |         |
| Age in years (median (IQR))            | 66.00 (53.00-68.00) | 60.00 (59.00-65.50) | 0.925   |
| Sex = M (%)                            | 9 (52.9) | 9 (81.8) | 0.226   |
| Race/ethnicity (%)                     |      |      | 0.763   |
| White                                  | 6 (35.3) | 6 (54.5) |         |
| Black                                  | 9 (52.9) | 4 (36.4) |         |
| Hispanic                               | 1 (5.9) | 0 (0.0) |         |
| Unknown                                | 1 (5.9) | 1 (9.1) |         |
| Comorbidities                          |      |      |         |
| CAD = Y (%)                            | 5 (29.4) | 2 (18.2) | 0.668   |
| Afib = Y (%)                           | 5 (29.4) | 2 (18.2) | 0.668   |
| CVA = Y (%)                            | 3 (17.6) | 5 (45.5) | 0.120   |
| PAD = Y (%)                            | 4 (23.5) | 3 (27.3) | 1.000   |
| Cancer = Y (%)                         | 4 (23.5) | 2 (18.2) | 1.000   |
| Smoking = Y (%)                        | 5 (29.4) | 10 (90.9) | 0.002*  |

**TABLE 1: Demographics and comorbidity profile of hospitalized COVID-19 patients according to APA status**

APA: antiphospholipid antibodies; No.: number; IQR: interquartile range; M: male; CAD: coronary artery disease; Afib: atrial fibrillation; CVA: cerebrovascular accident; PAD: peripheral artery disease; Y: yes. *Statistically significant.

There was no statistically significant difference in prognostic outcomes of interest between APA-positive and APA-negative groups, defined as a p-value <0.05. Six-month mortality in APA-negative and APA-positive patients was similar, i.e., 35.3% and 45.5%, respectively (p = 0.701). The rates of need for intubation and hemodialysis during hospitalization for COVID-19 infection were also similar. During the hospital stay for COVID-19 infection, in APA-negative and APA-positive groups, intubation was required in 58.8% and 63.6% of patients, respectively (p = 1.000), and hemodialysis was required in 17.6% and 18.2% of patients, respectively (p = 1.000). The rehospitalization rates were also similar between the two groups, i.e., 25.5% and 36.4% in APA-negative and APA-positive patients, respectively (p = 0.707). In APA-negative and APA-positive groups, 58.8% and 90.9% of patients required ICU admission, respectively, but the difference was not statistically significant (p = 0.099). The pattern of discharge disposition was also similar between APA-negative and APA-positive groups with in-hospital mortality rates of 35.3% and 36.4%, rates of discharge to a facility of 17.6% and 36.4%, rates of discharge to a group home of 11.8% and 0.0% and rates of discharge to the home of 35.3% and 27.3%, respectively (p = 0.599). These results are summarized in Table 2.
### Table 2: Prognostic outcomes in hospitalized patients COVID-19 patients according to APA status

| Prognostic Outcomes       | APA- | APA+ | p-Value |
|---------------------------|------|------|---------|
| No. of patients           | 17   | 11   |         |
| Alive* = Y (%)            | 11 (64.7) | 6 (54.5) | 0.701   |
| Vent# = Y (%)             | 10 (58.8) | 7 (63.6) | 1.000   |
| HD/CVVHD^ = Y (%)         | 3 (17.6) | 2 (18.2) | 1.000   |
| Rehospitalization (%)     |      |      | 0.707   |
| None                      | 13 (76.5) | 7 (63.6) |         |
| Once                      | 3 (17.6) | 2 (18.2) |         |
| Twice                     | 1 (5.9) | 2 (18.2) |         |
| Highest level of care (%) |      |      | 0.099   |
| Intermediate              | 7 (41.2) | 1 (9.1) |         |
| ICU                       | 10 (58.8) | 10 (90.9) |         |
| Disposition (%)           |      |      | 0.599   |
| Death                     | 6 (35.3) | 4 (36.4) |         |
| Facility                  | 3 (17.6) | 4 (36.4) |         |
| Group home                | 2 (11.8) | 0 (0.0) |         |
| Home                      | 6 (35.3) | 3 (27.3) |         |

APA: antiphospholipid antibodies; No.: number; Y: yes; Vent: ventilator; HD/CVVHD: hemodialysis/continuous veno-venous hemodialysis; ICU: intensive care unit. *Alive at six months after diagnosis. #Need for endotracheal intubation/ventilator during hospitalization for COVID-19 infection. ^Need for new dialysis secondary to renal failure during hospitalization for COVID-19 infection.

The laboratory values of interest were compared in APA-positive and APA-negative patients. There was no difference in median nadir and peak levels of hemoglobin (Hgb) during hospitalization for COVID-19 infection between the two groups. The median peak Hgb level was 12.40 grams per deciliter (g/dl) (IQR: 10.50-13.60 g/dl) in APA-negative patients in comparison to 11.30 g/dl (IQR: 10.70-13.10 g/dl) in APA-positive patients (p = 0.424). The median Hgb level nadir was 8.20 g/dl (IQR: 7.10-11.00 g/dl) in APA-negative patients in comparison to 9.50 g/dl (IQR: 7.10-10.00 g/dl) in APA-positive patients (p = 0.906). The median peak and nadir levels of median white blood cell (WBC) count were also similar. The median WBC count nadir was 5.21 x 1,000 cells per cubic millimeter of blood (x/µl) (IQR: 4.25-7.40 x 1,000 cells/µl) vs 7.00 x 1,000 cells/mm³ (IQR: 4.50-9.29 x 1,000 cells/mm³) in APA-negative and APA-positive patients, respectively (p = 0.438). The median peak WBC count was 17.34 x 1,000 cells/mm³ (IQR: 15.60-23.67 x 1,000 cells/mm³) vs 16.46 x 1,000 cells/mm³ (IQR: 12.62-20.53 x 1,000 cells/mm³) in APA-negative and APA-positive patients, respectively. There was no difference in nadir and peak levels of platelets (plt) between the two groups either. The median peak plt level was 311.00 x 1,000 cells/µl (IQR: 217.00-368.00 x 1,000 cells/µl) in APA-negative patients in comparison to 364.00 x 1,000 cells/µl (IQR: 346.00-432.50 x 1,000 cells/µl) in APA-positive patients (p = 0.115). The median plt level nadir was 146.00 x 1,000 cells/µl (IQR: 112.00-172.00 x 1,000 cells/µl) in APA-negative patients in comparison to 182.00 x 1,000 cells/µl (IQR: 115.00-207.00 x 1,000 cells/µl) in APA-positive patients (p = 0.480). The median nadir of absolute neutrophil count (ANC) was lower in APA-positive patients as compared to APA-negative patients, i.e., 2.80 x 1,000 cells/mm³ (IQR: 1.20-4.40 x 1,000 cells/mm³) vs 6.05 x 1,000 cells/mm³ (IQR: 4.10-7.47 x 1,000 cells/mm³) in APA-negative and APA-positive patients, respectively (p = 0.067). The median nadir of absolute lymphocyte count (ALC) was similar between two groups, i.e., 70.00 x 1,000 cells/mm³ (IQR: 40.50-100.00 x 1,000 cells/mm³) vs 65.00 x 1,000 cells/mm³ (IQR: 40.50-85.00 x 1,000 cells/mm³) in APA-positive and APA-negative patients, respectively (p = 0.067).

The median peak bilirubin level was similar between the two groups, i.e., 0.48 milligrams per deciliter (mg/dl) (IQR: 0.48-0.85 mg/dl) vs 0.50 mg/dl (IQR: 0.40-0.75 mg/dl) in APA-negative and APA-positive patients.
patients, respectively (p = 0.281). The median albumin level nadir was also similar, i.e., 2.75 grams per deciliter (g/dl) (IQR: 2.08-3.12 g/dl) vs 2.70 g/dl (IQR: 2.35-3.25 g/dl) in APA-negative and APA-positive patients, respectively (p = 0.845). The nadir of C-reactive protein (CRP) levels was in a higher range in APA-positive patients than in APA-negative patients, i.e., 73.35 mg/dl (IQR: 46.85-87.22 mg/dl) vs 22.45 mg/dl (IQR: 13.15-73.30 mg/dl) in APA-positive and APA-negative patients, respectively (p = 0.015). However, the median peak CRP levels were not different between the two groups, i.e., 190.00 mg/dl (IQR: 119.00-240.50 mg/dl) vs 131.00 mg/dl (IQR: 95.18-281.75 mg/dl) in APA-negative and APA-positive patients, respectively (p = 0.772). Other inflammatory marker levels such as ferritin, erythrocyte segmentation rate (ESR) and D-dimer were similar between the two groups. The median peak ESR was 47.00 mm/hr (IQR: 27.50-73.50 mm/hr) vs 85.00 mm/hr (IQR: 50.00-102.00 mm/hr) in APA-negative and APA-positive patients, respectively. The median peak D-dimer level was 5.03 microgram/milliliter (µg/ml) (IQR: 1.42-8.22 µg/ml) in APA-negative patients in comparison to 5.57 µg/ml (IQR: 1.77-4.12 µg/ml) in APA-positive patients (p = 0.754). The median peak ferritin level was 1173.00 microgram/liter (µg/l) (IQR: 372.00-2688.50 µg/l) in APA-negative patients in comparison to 795.00 µg/l (IQR: 173.50-783.00 µg/l) in APA-positive patients (p = 0.756). The median ferritin level nadir was 619.00 µg/l (IQR: 173.50-783.00 µg/l) in APA-negative patients in comparison to 795.00 µg/l (IQR: 547.50-1419.00 µg/l) in APA-positive patients (p = 0.223). The creatinine peak and lactate dehydrogenase (LDH) peak levels were also similar in the two groups. The median peak lactate dehydrogenase (LDH) level was 444.00 international units per liter (IU/l) (IQR: 292.00-700.00 IU/l) in APA-negative patients in comparison to 436.00 IU/l (IQR: 274.00-621.00 IU/l) in APA-positive patients (p = 0.881). The median creatinine level peak was 1.60 mg/dl (IQR: 1.23-5.68 mg/dl) in APA-negative patients in comparison to 1.58 mg/dl (IQR: 1.26-5.66 mg/dl) in APA-positive patients (p = 0.621). These results are summarized in Table 3.
### Laboratory Values

| Laboratory Values       | APA- | APA+ | p-Value |
|-------------------------|------|------|---------|
| No. of patients         | 17   | 11   |         |
| Peak Hgb (median (IQR)) | 12.40 (10.50-13.60) | 11.30 (10.70-13.10) | 0.424 |
| Hgb nadir (median (IQR))| 8.20 (7.10-11.00)    | 9.50 (7.10-10.00)    | 0.906 |
| WBC nadir (median (IQR))| 5.21 (4.25-7.40)     | 7.00 (4.50-9.29)     | 0.438 |
| Peak WBC (median (IQR)) | 17.34 (13.60-23.67)  | 16.46 (12.62-20.35)  | 0.832 |
| Peak PLT (median (IQR)) | 311.00 (217.00-368.00) | 364.00 (346.00-432.50) | 0.115 |
| PLT nadir (median (IQR))| 146.00 (112.00-172.00) | 182.00 (115.00-207.00) | 0.480 |
| ANC nadir (median (IQR))| 2.80 (1.20-4.40)     | 6.05 (4.10-7.47)     | 0.067 |
| ALC nadir (median (IQR))| 1.00 (0.55-1.30)     | 0.40 (0.30-0.55)     | 0.026* |
| Peak bili (median (IQR))| 0.65 (0.48-0.65)     | 0.50 (0.40-0.75)     | 0.281 |
| Alb nadir (median (IQR))| 2.75 (2.30-3.12)     | 2.70 (2.35-3.25)     | 0.843 |
| Peak ESR (median (IQR)) | 47.00 (27.50-73.50)  | 85.00 (50.00-102.00) | 0.186 |
| Peak D-dimer* (median (IQR)) | 5.03 (1.42-8.22) | 3.57 (1.77-4.12) | 0.734 |
| Peak ferritin* (median (IQR)) | 1173.00 (372.00-2688.50) | 793.00 (473.50-2402.00) | 0.736 |
| Fernin nadir* (median (IQR)) | 619.00 (173.50-783.00) | 793.00 (347.50-1419.00) | 0.223 |
| CRP nadir (median (IQR)) | 22.45 (13.15-73.30)  | 73.35 (46.85-87.22)  | 0.015* |
| Peak CRP (median (IQR)) | 190.00 (119.75-240.50) | 131.00 (95.18-281.75) | 0.772 |
| Peak LDH (median (IQR)) | 444.00 (292.00-700.00) | 436.00 (274.00-621.00) | 0.881 |
| Peak Cr (median (IQR)) | 1.60 (1.23-3.68)     | 1.58 (1.26-5.66)     | 0.621 |

**TABLE 3: Laboratory data of the hospitalized COVID-19 patients according to APA status**

APA: antiphospholipid antibodies; No.: number; Y: yes; Hgb: hemoglobin in grams per deciliter (g/dl); IQR: interquartile range; WBC: white blood cell count in cells x 1,000 per cubic millimeter of blood (/mm$^3$); PLT: platelets count x 1,000 per microliter of blood (/µl); ANC: absolute neutrophil count x 1,000 cells per cubic millimeter of blood (/mm$^3$); ALC: absolute lymphocyte count x 1,000 cells per cubic millimeter of blood (/mm$^3$); Bili: bilirubin in milligrams per deciliter (mg/dl) during hospitalization for COVID-19 infection; Alb: albumin in grams per deciliter (g/dl) during hospitalization for COVID-19 infection; ESR: erythrocyte sedimentation rate in millimeters/hour (mm/hr) during hospitalization for COVID-19 infection; CRP: C-reactive protein in mg/dl during hospitalization for COVID-19 infection; LDH: lactate dehydrogenase in international units per liter (IU/l) during hospitalization for COVID-19 infection; Cr: creatinine in mg/dl during hospitalization for COVID-19 infection. *D-dimer levels in microgram/milliliter (µg/ml) and ferritin levels in microgram/liter (µg/l). Statistical significance.

---

**Discussion**

APAs have been found to be associated with COVID-19 patients; however, data regarding their persistence and clinical implications are limited. LA- and aCL-positive titers have also been associated with other infections such as hepatitis C, cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, parvovirus and human immunodeficiency virus (HIV) [12]. In our study, the prevalence of APAs was found to be 39.3% in hospitalized COVID-19-positive patients when tested on samples collected within 48 hours of hospital admission for the management of COVID-19 infection. A previous study involving over a thousand patients showed an APA positivity prevalence of 7.1% in hospitalized patients [13]. Hospitalized COVID-19 patients have a higher prevalence of APAs as compared to historic studies involving hospitalized patients without COVID-19 infection.

Looking at APA subgroups, our study found that 25% of the hospitalized COVID-19 patients had positive aCL IgM, 10.71% had positive aCL IgG, 7.14 % had positive aβ2GPI IgM and 50% of the tested patients had positive LA. β2GPI IgG was not seen in any patients. About 14.2% of patients had more than one positive APA test. No patient had a triple positive (positive testing for all three APAs) profile. A systematic review involving COVID-19 patients found the prevalence of LA ranging from 35% to 92% in intensive care unit (ICU) patients; aCL IgG and IgM up to 52% and up to 40% of patients, respectively; and aβ2GPI IgG and IgM up to 59% and up to 54% of patients, respectively. One percent and 12% of patients were found to have a triple positive APA profile [14]. These numbers corresponding to APA subgroups in the systematic review are

---

2022 Kahlon et al. Cureus 14(8): e27862. DOI 10.7759/cureus.27862
higher than in our study. However, the systematic review included only ICU patients, and our study included all hospitalized patients. This difference in results between these two studies could potentially indicate a higher prevalence of APAs in ICU patients than in all hospitalized patients.

There was no difference in demographic profile or comorbidity profile in APA-positive and APA-negative patients in our study. A statistically significant association between smoking history with APA positivity status was noted in our study. Ninety-one percent of patients who tested positive for APAs were smokers as compared to only 30% of patients in the APA-negative group. An association between smoking and APA positivity has been demonstrated in other studies involving non-COVID-19 patients too, and a higher risk of vascular events in these patients has been demonstrated [15,16]. If we extrapolate data from non-COVID-19 patients, it is possible that APA positivity may be associated with a higher risk of vascular events in hospitalized COVID-19 patients with a smoking history as well, but this hypothesis cannot be tested in our study given the small number of patients and the retrospective nature of the study. The smokers with COVID-19 infection must be studied in prospective studies to determine the prognostic and predictive role of APAs in this patient population specifically.

The thromboembolic events including VTE and ATE have been reported in COVID-19 patients. These thromboembolic events in COVID-19 are associated with high mortality [17]. Although high titers of APAs in COVID-19 patients have been seen, the correlation between thrombotic events or mortality and APA positivity in COVID-19 remains under investigation. So far, no association between APA positivity and inhospital mortality has been found [18]. There are hardly any studies that looked at the presence of APA positivity and long-term mortality in COVID-19 patients which was evaluated in our study. We found that there was no difference in long-term outcomes, specifically six-month mortality between the APA-positive or APA-negative patients. Also, there was no difference in prognostic outcomes determining disease severity in this study, i.e., in-hospital mortality, rehospitalizations, need for mechanical ventilation, hemodialysis or discharge disposition to a facility between these two groups. In contrast, a previous longitudinal study done by Trahtemberg et al. involving APA-positive patients with respiratory failure admitted to intensive care involving COVID-19-positive and COVID-19-negative patients found that positive APA serology had an association with more severe disease regardless of COVID-19 status [19]. This difference in results might be due to the difference in patients included in the two studies. Our study included all hospitalized patients, and the study by Trahtemberg et al. included a sicker ICU patient population [19]. Trahtemberg et al. did not find any association between APA positivity and increased thrombotic risk [19]. Unfortunately, the retrospective data from our study did not allow us to assess VTE risk in these patients as most patients did not have imaging studies done to assess VTE.

We compared the selected laboratory values between APA-positive and APA-negative patient groups. In our study, there was no correlation between APA serum positivity and most of the hematologic parameters, i.e., peak and nadir hemoglobin level, platelet count, total leukocyte count and absolute neutrophil count. The only exception was the lower nadir of absolute lymphocyte count (ALC) in APA-positive patients. As of note, the low lymphocyte count is a known poor prognostic marker for COVID-19 infection and has an association with increased COVID-19 mortality [20]. However, our study demonstrates lower ALC in APA-positive group; there was no association with increased mortality in this group. A single-arm meta-analysis from this study comparing non-severe and severe COVID-19 cases showed severe cases that had lower platelet counts (165.12 in severe cases, 190.09 in non-severe cases), D-dimer (0.49 in severe cases, 0.27 in non-severe cases) and fibrinogen (4.34 in severe cases, 3.19 in non-severe cases) [21]. There was no correlation between APA positivity and these laboratory parameters associated with severe COVID-19 infection, i.e., D-dimer levels, low platelet levels and high fibrinogen levels. The inflammatory markers such as ferritin and ESR were also similar. The nadir of CRP levels was higher in APA-positive patients suggesting more inflammation in this subgroup. The laboratory values determining organ dysfunction and hence the disease severity such as creatinine level, bilirubin, LDH and albumin were similar in the two groups.

We acknowledge the limitations of our study. One limitation of our study is the small sample size. It was primarily limited by a number of patients with available viable serum samples for testing APA levels. We do not have serial APA levels as this is not a prospective study. Being a retrospective study, we did not have imaging studies such as CTA or venous Doppler ultrasound available for most of these patients to detect and report the presence or absence of asymptomatic thrombosis which would have been an important adverse effect of interest. Also, confounding variables cannot be adjusted due to the study’s retrospective nature. Post hoc power analysis was computed on the significant variables found in the study. While the association between smoking status and APA positivity was well-powered (95.8%), it is likely that the results from APA positivity and CRP nadir as well as ALC nadir association are underpowered in our study (35.5% and 64.8%, respectively).

Conclusions

The prevalence of APA positivity in hospitalized COVID-19 patients is higher in our study than in historical studies involving non-COVID-19 hospitalized patients, particularly in smokers. However, there is no correlation between APA positivity and disease severity. Also, six-month mortality in APA-positive patients is the same as in APA-negative patients. At present, it remains unclear whether these antibodies are just bystanders or play a pathogenic role in COVID-19-related hypercoagulability. We do not recommend routine
testing of APAs in COVID-19 patients. However, further prospective studies to elucidate the persistence and clinical implications of APAs are needed, particularly in smokers.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. University of Toledo Medical Center’s biomedical institutional review board issued approval 300722-UT. The approval for this retrospective study conducted at the University of Toledo Medical Center was obtained from the biomedical institutional review board (IRB) (IRB number: 300722-UT). **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**Acknowledgements**

We appreciate help from our laboratory personnel Lyon Collins with this project. Data are available on reasonable request. The data are available on request to principal investigator (PI), Ragheb Assaly, ragheb.assaly@utoledo.edu or Hematology/Oncology (Hem/Onc) program coordinator, Beth Fields, beth.fields@utoledo.edu or our statistician, William Barnett, william.barnett@utoledo.edu and are stored as deidentified data in a password protected file in the Hematology and Oncology Z drive folder.

**References**

1. Cai S, Chen S, Li X, Liu S, Wang F: Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020, 18:1421-4. 10.1111/jth.14850
2. Ali EW, Ibrahim IK: Multi-factorial mechanism behind COVID-19 related thrombosis. Med Arch. 2022, 76:62-5. 10.5455/medarch.2022.76:62-65
3. Sneath L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P: Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004, 351:2611-8. 10.1056/NEJMoa041747
4. Davidson JA, Warren-Gash C: Cardiovascular complications of acute respiratory infections: current research and future directions. Expert Rev Anti Infect Ther. 2019, 17:939-42. 10.1080/14787210.2019.1689817
5. Zhou F, Yu T, Du R, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020, 395:1054-62. 10.1016/S0140-6736(20)30566-3
6. Gallagher PE, Ferrario CM, Taillant EA: Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol. 2008, 295:H2573-9. 10.1152/ajpheart.00426.2008
7. Mendoza-Torres E, Oyarzun A, Mondaca-Ruff D, et al.: ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension. Ther Adv Cardiovasc Dis. 2015, 9:217-37. 10.1177/175394471597625
8. Meroni PL, Borghi MO: Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer. Ann Rheum Dis. 2021, 80:1105-7. 10.1136/annrheumdis-2021-220520
9. Favalaro EJ, Henry BM, Lippi G: COVID-19 and antiphospholipid antibodies: time for a reality check?. Semin Thromb Hemost. 2022, 48:72-92. 10.1055/s-0041-1728832
10. Bowles L, Plattow S, Varney N, et al.: Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med. 2020, 383:288-90. 10.1056/NEJMoa2013566
11. Zhang Y, Xiao M, Zhang S, et al.: Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020, 382:e38. 10.1056/NEJMoa2007575
12. Uthman IW, Gharavi AE: Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002, 32:256-63. 10.1055/s-2002-308303
13. Schved JF, Dupuy-Fons C, Biron C, Quere J, Janhon C: A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis. 1994, 24:175-82. 10.1119/000217099
14. Foret T, Dufrost V, Salomon Du Mont L, et al.: Systematic review of antiphospholipid antibodies in COVID-19 patients: culprits or bystanders?. Curr Rheumatol Rep. 2021, 23:65. 10.1007/s11926-021-01029-3
15. Binder SR, Litwin CM: Anti-phospholipid antibodies and smoking: an overview. Clin Rev Allergy Immunol. 2017, 53:1-15. 10.1007/s12016-016-8565-4
16. Keswani SC, Chaunah N: Antiphospholipid syndrome. J R Soc Med. 2002, 95:536-42.
17. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B: Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EiClinicalMedicine. 2020, 29:100639. 10.1016/j.eclinm.2020.100639
18. Taha M, Samavati L: Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021, 7:e001580. 10.1136/rmdopen-2021-001580
19. Tzankov A, Rottapel R, dos Santos CC, Sluksky AS, Baker A, Fritzler MJ: Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann Rheum Dis. 2021, 80:1236-40. 10.1136/annrheumdis-2021-220206
20. Illg Z, Muller G, Muller M, Nippert J, Allen B: Analysis of absolute lymphocyte count in patients with COVID-19. Am J Emerg Med. 2021, 46:16-9. 10.1016/j.ajem.2021.02.054
21. Lin J, Yan H, Chen H, et al.: COVID-19 and coagulation dysfunction in adults: a systematic review and meta-
